Blog/Recursos
Artículos técnicos
1. AI in Drug Discovery & Design
Generative AI Drug Design Platforms
AI-generated molecular structures for novel therapeutics.
Companies like Anagenex explore chemical spaces 1000x larger than conventional methods.
Business Value: 18-24 months faster discovery, 30% cost savings, $2.1B in partnerships.
Sources: Nature, Market Logic.
AI-Enhanced Drug Repurposing for Oncology
Graph neural networks (GNNs) identify novel uses for existing compounds.
Trained on 500k+ drug-target interactions, proposed 12 candidates for glioblastoma repurposing.
Business Value: $300M saved, 2x faster validation, 18% higher trial success.
Sources: Cell Reports Medicine (2023).
AI Drug Repurposing Engine
2. AI in Clinical Trials & Patient Recruitment
AI-Driven Clinical Trial Recruitment for Rare Diseases
ML algorithms accelerate patient matching for rare disease trials (e.g., ALS, cystic fibrosis).
Integrates EHRs, genomic data, and patient advocacy forums.
Business Value: 50-60% faster recruitment, 30% cost reduction, 25% improved diversity.
Sources: Nature Medicine (2023), NEJM AI (2024).
AI-Optimized Clinical Trials
Novartis' AI systems analyze genetic profiles/EHR data for trial design and patient matching.
Predicts retention risks and adjusts protocols in real-time.
Business Value: 22% faster enrollment, 17% lower dropout rates, $120M per-trial cost reduction.
Sources: Bench International, Litslink.
Pfizer's AI in COVID-19 Vaccine Trial Data Analysis
AI used to speed up data cleaning and analysis in clinical trials.
Reduced data cleaning time from 30 days to 22 hours.
Business Value: Significant time savings, faster decision-making.
Sources: Pfizer's Official Website.
3. AI in Manufacturing & Supply Chain
IoT-Enabled Smart Manufacturing
Roche's sensor networks monitor 150+ equipment parameters for predictive maintenance.
AI predicts failures with 94% accuracy and auto-adjusts environmental controls.
Business Value: 33% fewer production halts, 0.003% defect rate, $45M annual savings.
Sources: Arkangel, Supply Chain Wizard.
Blockchain Drug Traceability
GSK's blockchain solution tracks 28M drug units annually with smart contracts and AI anomaly detection.
Business Value: 99.97% counterfeit prevention, 83% faster recall execution, $780M risk mitigation.
Sources: Arkangel, Supply Chain Wizard.
4. AI in Regulatory & Post-Market Surveillance
Generative AI for Regulatory Document Automation
NLP models automate creation of regulatory submission drafts (e.g., CSRs, safety narratives).
Business Value: 70% faster drafting, 40% reduction in QC cycles, $2M/year saved.
Sources: McKinsey.
Real-World Evidence (RWE) Analytics Platform
Federated learning analyzes decentralized patient data for post-market surveillance.
Detects adverse drug reactions (ADRs) 3x faster than manual methods.
Business Value: 30% faster ADR detection, 15% lower post-market study costs, 4-month FDA approval acceleration.
Sources: The Lancet Digital Health (2023).
5. AI in Personalized Medicine & Patient Care
Causal AI Digital Twins
Aitia's Gemini platform creates virtual patient twins for target identification.
Applied to neurodegenerative disorders and oncology.
Business Value: 40% improvement in trial success rates, $350M saved per approved drug.
Sources: Nature, Digital Defynd.
Roche and GOSH's AI for Personalized Healthcare
AI co-develops digital tools for children with rare diseases.
Business Value: Better data utilization, improved patient care.
Sources: ABPI Case Study.
6. AI in Operational Efficiency
Johnson & Johnson's Intelligent Automation for Operational Efficiency
AI and RPA improve efficiency, reduce costs, and increase accuracy in business operations.
Business Value: Increased efficiency, cost reduction, improved accuracy.
Sources: AIX Case Study.
Podcast de innovación farmacéutica

IA en Asuntos Regulatorios Farmacéuticos
This compilation of texts primarily explores the increasing role of artificial intelligence (AI) within the pharmaceutical industry, specifically in regulatory affairs. The main article from Drug Discovery Today highlights AI's potential to streamline regulatory processes, automate tasks like data extraction and dossier filing, and enhance efficiency. Other listed publications and cited articles further examine AI's impact on areas such as drug discovery, development, manufacturing, quality control, and regulatory compliance, while also acknowledging challenges and ethical considerations associated with its implementation. Overall, the sources suggest a significant shift towards leveraging AI to modernize and improve various facets of the pharmaceutical sector.